China Cabinet Proposes Five-Year Plan For Greater Drug, Device Quality
This article was originally published in PharmAsia News
China’s State council proposed a five-year plan, through 2015, that would raise drug standards and quality across all categories and lift standards for medical equipment.
You may also be interested in...
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.
Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.